This transfer does not include biometrics or commercialization-related capabilities, enabling Cytel to maintain its strategic focus and continue serving the Nordic market as a leading provider of quantitative and real-world evidence solutions, the company states.

“This transfer reinforces our core mission: helping Nordic biotech companies accelerate their drug development with high-quality, integrated expertise, and strong local presence,” says Anders Göransson, CEO of LINK Medical.

“This is an excellent fit, and we are excited to become part of LINK Medical. Together, we strengthen our ability to drive complex development programs from start to finish,” says Maria Lundberg, who is also transitioning from SDS to LINK Medical as Early-Stage Services & Integration Lead.